Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02850276 · ClinicalTrials.gov registry record · Early Phase 1
Autonomic Neuropathy, GI Motility, and Inflammation in HIV
A Early Phase 1 study, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 76
- Enrollment target
NCT02850276: Completed Early Phase 1 study, sponsored by Icahn School of Medicine at Mount Sinai.
NCT02850276 is a Early Phase 1 study that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 76 participants, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (43% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02850276, a Early Phase 1 study, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 76 participants
- Enrollment target
Study Summary
The purpose of this study is to explore a possible link between the autonomic nervous system and immune function in patients with HIV. Sometimes HIV can cause these nerves to function abnormally, this is called HIV-associated autonomic neuropathy (HIV-AN). HIV-AN is a condition that is different from person to person. In some people it causes no symptoms and is not harmful, in others it may cause symptoms such as dizziness or lightheadedness, nausea, vomiting, diarrhea, constipation, or problems urinating. Most people with HIV-AN don't know that they have it. One of the important nerves in the autonomic nervous system is the vagus nerve. Abnormal function of the vagus nerve may cause stomach and intestinal slowing, which could lead to an overgrowth of bacteria. The body senses these bacteria and tries to fight them, leading to inflammation. In this study the researchers will test whether abnormal function of the vagus nerve in HIV is associated with stomach slowing and overgrowth of bacteria, and if a drug called pyridostigmine can help.
Primary Outcome
Breath Test at week 8 as compared to baseline. Breath test results is the rise in the combined hydrogen and methane during the breath test.
Interventions
- DRUG Pyridostigmine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2015-11 |
| Est. Completion | 2018-06-01 |
| Phase | Early Phase 1 |
What the finished NCT02850276 record still lists
NCT02850276 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 76 participants, a relatively small participant target, above the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (43% higher).
The record links to 0 conditions, and to 1 intervention - of which Pyridostigmine is the first listed.
NCT02850276 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02850276 about?
NCT02850276 is a clinical study titled "Autonomic Neuropathy, GI Motility, and Inflammation in HIV". The purpose of this study is to explore a possible link between the autonomic nervous system and immune function in patients with HIV. Sometimes HIV can cause these nerves to function abnormally, this is called HIV-associated autonomic neuropathy (HIV-AN). HIV-AN is a condition that is different fro...
What is the current status of trial NCT02850276?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 76 participants. The study started on 2015-11. Estimated completion is 2018-06-01.
What interventions are being tested in trial NCT02850276?
The interventions under investigation include: Pyridostigmine (DRUG).
Who is sponsoring clinical trial NCT02850276?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02850276's enrollment target sits among peer trials
76 303rd of 2000 higher than 1,698 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02615184 · 76 participants · Phase 2
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
- NCT02821741 · 76 participants · NA
Effects of External Ear Stimulation on Pain Perception and Mood
- NCT03019757 · 76 participants
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
- NCT03353584 · 76 participants · NA
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia